This study provides insight into target organs for FGF-based drugs and demonstrates that hepatic KLB remains expressed throughout MASLD stages, supporting the use of FGF-based drugs in early and advanced stages of MASLD. Here, KLB is linked to metabolic dysfunction-associated steatotic liver disease.